One of last year’s beneficiaries of Sub-measure 1.1.1 of the Intelligent Development Operational Program 2014-2020 is Bioceltix, a Wroclaw biotechnology start-up, implementing on the world market veterinary biopharmaceuticals based on mesenchymal stem cells (MSC). The technology developed by the Bioceltix team allows the use of allogeneic stem cells in the therapy without the need to always take the source material from the patient. The developed solution means serial production of a biological medicine and its availability immediately (off the shelf) in a veterinary clinic. None of the companies in Europe offers this – Business Insider.
